title: Autologous CD34-selected blood progenitor cell transplants for patients with advanced multiple myeloma.
abstract: Fifty-five patients with advanced multiple myeloma received purified CD34-selected peripheral blood progenitor cell transplants following myeloablative chemotherapy. A median of 4.1 x 10(6) CD34 cells/kg (range 1.2-30.7) were infused after busulfan (14 mg/kg) and cyclophosphamide (120 mg/kg); granulocyte-macrophage colony-stimulating factor was used until hematopoietic recovery. Median time to neutrophils >0.5 x 10(9)/l and platelets >20 x 10(9)/l were 12 days (range 10-16 and 8-184 days, respectively). Median follow-up of survivors from the time of transplantation is 33 months (range 7 to 44 months). Thirty-one patients are alive, 19 progression-free. Median progression-free survival is 14 months. Actuarial 3-year progression-free and overall survival are 29+/-14% and 47+/-17%. CD34-selection of peripheral blood progenitor cells provides effective hematopoietic support with significant progression-free and overall survival.
authors.affiliation: Department of Medicine, Jonsson Comprehensive Cancer Center, UCLA School of Medicine, Los Angeles, CA 90095, USA.
authors.forename: G
authors.initials: G
authors.lastname: Schiller
authors.forename: R
authors.initials: R
authors.lastname: Vescio
authors.forename: C
authors.initials: C
authors.lastname: Freytes
authors.forename: G
authors.initials: G
authors.lastname: Spitzer
authors.forename: M
authors.initials: M
authors.lastname: Lee
authors.forename: C H
authors.initials: CH
authors.lastname: Wu
authors.forename: J
authors.initials: J
authors.lastname: Cao
authors.forename: J C
authors.initials: JC
authors.lastname: Lee
authors.forename: A
authors.initials: A
authors.lastname: Lichtenstein
authors.forename: M
authors.initials: M
authors.lastname: Lill
authors.forename: R
authors.initials: R
authors.lastname: Berenson
authors.forename: J
authors.initials: J
authors.lastname: Berenson
mesh_terms: D000328:Adult; D000368:Aged; D018952:Antigens, CD34 / Q000378:metabolism; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage; D002066:Busulfan / Q000008:administration & dosage; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage; D005260:Female; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000008:administration & dosage; D006410:Hematopoiesis; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects; D006412:Hematopoietic Stem Cells / Q000276:immunology; D006801:Humans; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy / Q000401:mortality / Q000628:therapy*; D015996:Survival Rate; D013997:Time Factors; D014182:Transplantation, Autologous
chemical_list: D018952:Antigens, CD34; D016178:Granulocyte-Macrophage Colony-Stimulating Factor; D003520:Cyclophosphamide; D002066:Busulfan